GI Cancer
GI Cancer
Advertisement
Emily MenendezGastroesophageal Cancer | December 9, 2024
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
Read More
Emily MenendezBile Duct Cancer | December 4, 2024
The GAP system was found to predict actionable genetic alterations including FGFR2 and IDH.
Emily MenendezColorectal Cancer | December 4, 2024
Campylobacter bacteria have been found to be enriched in primary CRC lesions of patients with metastasis.
Emily MenendezColorectal Cancer | December 3, 2024
The phase 3 KEYNOTE-177 study compared the efficacy of pembrolizumab with chemotherapy for the treatment of MSI-H/dMMR mCRC.
Emily MenendezPancreatic Cancer | December 3, 2024
The survival rate benefit increased over time for patients treated with TTFields, with a 13% improvement in OS at 12 months.
Emily MenendezGEP-NETs | November 23, 2024
A blood-based, non-invasive classifier can serve as an optional tool for conventional methods in the detection of NETs.
Emily MenendezHepatocellular Carcinoma | November 23, 2024
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
Emily MenendezBile Duct Cancer | November 21, 2024
HERIZON-BTC-01 marks the largest phase IIb clinical trial to date for patients with previously treated HER2-positive disease.
Laura LitwinHepatocellular Carcinoma | December 3, 2024
A recent analysis reviewed patient-level data to identify the relationship between pathological response and relapse.
Kimmie Ng, MD, MPHGI Cancer | November 27, 2024
Dr. Kimmie Ng shares the experiences that drive her dedication to seeking improved patient outcomes in GI oncology care.
Laura LitwinPancreatic Cancer | November 20, 2024
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
Emily MenendezGastric Cancer | November 19, 2024
A recent systematic review evaluated the relationship between NLR and the prognosis of patients who receive NAC.
Emily MenendezPancreatic Cancer | November 19, 2024
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
Emily MenendezColorectal Cancer | November 9, 2024
Studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
Emily MenendezBile Duct Cancer | November 1, 2024
In several different types of cancer, tumor budding is linked to poor survival outcomes.
Laura LitwinGastric Cancer | November 20, 2024
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
Laura LitwinPancreatic Cancer | October 31, 2024
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
Emily MenendezGastric Cancer | October 30, 2024
The SOX chemotherapy regimen for gastric cancer consists of S-1, an oral fluoropyrimidine, in combination with oxaliplatin.
Emily MenendezUnresectable HCC | October 30, 2024
Repeated use of TACE can impair liver function and stimulate tumor angiogenesis.
Richard S. Finn, MDHepatocellular Carcinoma | October 29, 2024
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
Advertisement
Advertisement
Advertisement
Latest News

December 11, 2024